Linked Life Data

18565886

Source:http://linkedlifedata.com/resource/pubmed/id/18565886

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
18
pubmed:dateCreated
2008-6-20
pubmed:abstractText
To determine the clinical and biologic effects of bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular carcinoma (HCC).
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1527-7755
pubmed:author
pubmed:issnType
Electronic
pubmed:day
20
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2992-8
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:18565886-Adult, pubmed-meshheading:18565886-Aged, pubmed-meshheading:18565886-Aged, 80 and over, pubmed-meshheading:18565886-Angiogenesis Inhibitors, pubmed-meshheading:18565886-Animals, pubmed-meshheading:18565886-Antibodies, Monoclonal, pubmed-meshheading:18565886-Antibodies, Monoclonal, Humanized, pubmed-meshheading:18565886-Carcinoma, Hepatocellular, pubmed-meshheading:18565886-Chemokine CXCL12, pubmed-meshheading:18565886-Disease-Free Survival, pubmed-meshheading:18565886-Humans, pubmed-meshheading:18565886-Infusions, Intravenous, pubmed-meshheading:18565886-Liver Neoplasms, pubmed-meshheading:18565886-Magnetic Resonance Angiography, pubmed-meshheading:18565886-Male, pubmed-meshheading:18565886-Middle Aged, pubmed-meshheading:18565886-Neovascularization, Pathologic, pubmed-meshheading:18565886-Vascular Endothelial Growth Factor A
pubmed:year
2008
pubmed:articleTitle
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.
pubmed:affiliation
Department of Medicine, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032-3784, USA. aas54@columbia.edu
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II, Research Support, N.I.H., Extramural